Movement Alert｜Sino Biopharmaceutical Falls 3.07% in Regular Trading, Morgan Stanley Cuts Target Price Amid Broader Pharma Sector Selloff

Market Focus06-03 10:18

On June 3, Sino Biopharmaceutical fell 3.07% in regular trading, trading at 4.73 HKD/share with trading volume of approximately 70.08 million HKD. The decline was primarily triggered by Morgan Stanley's downgrade of the target price from 8.3 HKD to 7.8 HKD while maintaining an Overweight rating.

Morgan Stanley incorporated the newly licensed bepirovirsen (HBV ASO) into its model, expecting the product to begin contributing revenue from 2027. The bank also removed dividend income assumptions from Sinovac LS starting from 2026 per management guidance, resulting in EPS forecast cuts of 8%, 7%, and 7% for 2026 through 2028 respectively. Working capital and capital expenditure assumptions were also adjusted to better reflect recent operational trends.

The broader pharmaceuticals sector experienced significant selling pressure, with CSPC Pharma down 5.15%, Hengrui Pharma down 3.99%, Fosun Pharma down 3.04%, Hansoh Pharma down 2.77%, and Luye Pharma down 2.27%, amplifying the stock-specific weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1110585666?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 10:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110585666","market":"us","top_or_hot":-1,"title":"Movement Alert｜Sino Biopharmaceutical Falls 3.07% in Regular Trading, Morgan Stanley Cuts Target Price Amid Broader Pharma Sector Selloff","media":"Market Focus","content":"<p><p>On June 3, Sino Biopharmaceutical fell 3.07% in regular trading, trading at 4.73 HKD/share with trading volume of approximately 70.08 million HKD. The decline was primarily triggered by Morgan Stanley's downgrade of the target price from 8.3 HKD to 7.8 HKD while maintaining an Overweight rating.</p><p>Morgan Stanley incorporated the newly licensed bepirovirsen (HBV ASO) into its model, expecting the product to begin contributing revenue from 2027. The bank also removed dividend income assumptions from Sinovac LS starting from 2026 per management guidance, resulting in EPS forecast cuts of 8%, 7%, and 7% for 2026 through 2028 respectively. Working capital and capital expenditure assumptions were also adjusted to better reflect recent operational trends.</p><p>The broader pharmaceuticals sector experienced significant selling pressure, with CSPC Pharma down 5.15%, Hengrui Pharma down 3.99%, Fosun Pharma down 3.04%, Hansoh Pharma down 2.77%, and Luye Pharma down 2.27%, amplifying the stock-specific weakness.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Sino Biopharmaceutical Falls 3.07% in Regular Trading, Morgan Stanley Cuts Target Price Amid Broader Pharma Sector Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Sino Biopharmaceutical Falls 3.07% in Regular Trading, Morgan Stanley Cuts Target Price Amid Broader Pharma Sector Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-03 10:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 3, Sino Biopharmaceutical fell 3.07% in regular trading, trading at 4.73 HKD/share with trading volume of approximately 70.08 million HKD. The decline was primarily triggered by Morgan Stanley's downgrade of the target price from 8.3 HKD to 7.8 HKD while maintaining an Overweight rating.</p><p>Morgan Stanley incorporated the newly licensed bepirovirsen (HBV ASO) into its model, expecting the product to begin contributing revenue from 2027. The bank also removed dividend income assumptions from Sinovac LS starting from 2026 per management guidance, resulting in EPS forecast cuts of 8%, 7%, and 7% for 2026 through 2028 respectively. Working capital and capital expenditure assumptions were also adjusted to better reflect recent operational trends.</p><p>The broader pharmaceuticals sector experienced significant selling pressure, with CSPC Pharma down 5.15%, Hengrui Pharma down 3.99%, Fosun Pharma down 3.04%, Hansoh Pharma down 2.77%, and Luye Pharma down 2.27%, amplifying the stock-specific weakness.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1110585666","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110585666","pubTimestamp":1780453126,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 3, Sino Biopharmaceutical fell 3.07% in regular trading, trading at 4.73 HKD/share with trading volume of approximately 70.08 million HKD. The decline was primarily triggered by Morgan...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"动向提示|中国生物制药常规交易跌3.07%，大摩在更广泛的制药板块抛售中下调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"On June 3, Sino Biopharmaceutical fell 3.07% in regular trading, trading at 4.73 HKD/share with trading volume of approximately 70.08 million HKD. The decline was primarily triggered by Morgan Stanley's downgrade of the target price from 8.3 HKD to 7.8 HKD while maintaining an Overweight rating.Morgan Stanley incorporated the newly licensed bepirovirsen (HBV ASO) into its model, expecting the product to begin contributing revenue from 2027. The bank also removed dividend income assumptions from Sinovac LS starting from 2026 per management guidance, resulting in EPS forecast cuts of 8%, 7%, and 7% for 2026 through 2028 respectively. Working capital and capital expenditure assumptions were also adjusted to better reflect recent operational trends.The broader pharmaceuticals sector experienced significant selling pressure, with CSPC Pharma down 5.15%, Hengrui Pharma down 3.99%, Fosun Pharma down 3.04%, Hansoh Pharma down 2.77%, and Luye Pharma down 2.27%, amplifying the stock-specific weakness.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1110585666","isCrawlerRequest":true}